Terms: = Kidney tumors AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
4 results:
1. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.
Santoni M; Pantano F; Amantini C; Nabissi M; Conti A; Burattini L; Zoccoli A; Berardi R; Santoni G; Tonini G; Santini D; Cascinu S
Biochim Biophys Acta; 2014 Apr; 1845(2):221-31. PubMed ID: 24480319
[TBL] [Abstract] [Full Text] [Related]
2. Targeting pim kinase enhances the activity of sunitinib in renal cell carcinoma.
Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
[TBL] [Abstract] [Full Text] [Related]
3. Radiofrequency ablation of renal tumours: diagnostic accuracy of contrast-enhanced ultrasound for early detection of residual tumour.
Hoeffel C; Pousset M; Timsit MO; Elie C; Méjean A; Merran S; Tranquart F; Khairoune A; Joly D; Richard S; Hélénon O; Correas JM
Eur Radiol; 2010 Aug; 20(8):1812-21. PubMed ID: 20204642
[TBL] [Abstract] [Full Text] [Related]
4. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract] [Full Text] [Related]
